视神经脊髓炎
光谱紊乱
打开标签
医学
句号(音乐)
多发性硬化
儿科
临床试验
内科学
精神科
物理
声学
作者
Bruce Cree,Ho Jin Kim,Brian G. Weinshenker,Sean J. Pittock,Dean M. Wingerchuk,Kazuo Fujihara,Friedemann Paul,Gary Cutter,Romain Marignier,Ari Green,Orhan Aktaş,Hans‐Peter Hartung,Dewei She,William A. Rees,Michael Smith,Daniel Cimbora,Eliezer Katz,Jeffrey L. Bennett
标识
DOI:10.1016/s1474-4422(24)00077-2
摘要
Inebilizumab, an anti-CD19 B-cell-depleting antibody, demonstrated safety and efficacy in neuromyelitis optica spectrum disorder in the randomised controlled period of the N-MOmentum trial. Here, end-of-study data, including the randomised controlled period and open-label extension period, are reported.
科研通智能强力驱动
Strongly Powered by AbleSci AI